Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial-论文-万方医学网

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial

导出原文传递

翻译打印收藏纠错

作者： Howell, Sacha J. ^[1] ; Casbard, Angela ^[2] ; Carucci, Margherita ^[3] ; Ingarfield, Kate ^[4] ; Butler, Rachel ^[5] ; Morgan, Sian ^[6] ; Meissner, Magdalena ^[7] ; Bale, Catherine ^[8] ; Bezecny, Pavel ^[9] ; Moon, Sarah ^[10] ; Twelves, Chris ^[11] ; Venkitaraman, Ramachandran ; Waters, Simon ; de Bruin, Elza C. ; Schiavon, Gaia ; Foxley, Andrew ; Jones, Robert H.

作者单位： Velindre Cancer Centre,Velindre Canc Ctr ^[1] Ctr Trials Res,Cardiff Univ ^[2] All Wales Lab Genet Serv ^[3] Cardiff & Vale Univ Hlth Board ^[4] Betsi Cadwaladr Univ Hlth Board ^[5] Blackpool Teaching Hosp NHS Fdn Trust ^[6] Univ Hosp Morecambe Bay NHS Fdn Trust ^[7] Univ Leeds ^[8] Ipswich Hosp NHS Trust ^[9] Velindre Canc Ctr ^[10] Oncol R&D,AstraZeneca ^[11]

关键词 RESISTANT PROSTATE-CANCER DOUBLE-BLIND MULTICENTER ALPELISIB PREDNISOLONE MONOTHERAPY MUTATIONS

发布时间 2022-11-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除